GSK plc (GSK)
| Market Cap | 75.14B |
| Revenue (ttm) | 40.74B |
| Net Income (ttm) | 4.07B |
| Shares Out | 4.08B |
| EPS (ttm) | 0.98 |
| PE Ratio | 18.44 |
| Forward PE | 8.12 |
| Dividend | $1.60 (4.27%) |
| Ex-Dividend Date | May 16, 2025 |
| Volume | 6,018,253 |
| Open | 36.63 |
| Previous Close | 36.62 |
| Day's Range | 36.51 - 37.50 |
| 52-Week Range | 31.72 - 45.93 |
| Beta | 0.27 |
| Analysts | Hold |
| Price Target | 47.00 (+25.77%) |
| Earnings Date | Apr 30, 2025 |
About GSK
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, infectious, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, inflammation, and other specialty medicine product... [Read more]
Financial Performance
In 2024, GSK's revenue was 31.38 billion, an increase of 3.46% compared to the previous year's 30.33 billion. Earnings were 2.58 billion, a decrease of -47.75%.
Financial numbers in GBP Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for GSK stock is "Hold." The 12-month stock price forecast is $47.0, which is an increase of 25.77% from the latest price.
News
ITeos, GSK discontinue lung cancer therapy development
iTeos Therapeutics and partner GSK said on Tuesday that they terminated the development of their experimental lung cancer therapy after its failure to significantly improve progression free survival i...
India's GlaxoSmithKline Pharma reports profit rise on strong demand
India's GlaxoSmithKline Pharmaceuticals reported a higher fourth-quarter profit on Tuesday, led by steady demand for its generic drugs.
Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to know
President Donald Trump wants to lower U.S. drug costs by linking prices to those paid in other developed countries – a move that experts say could face a challenging path to becoming a reality. Trump...
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
Pharmaceutical stocks slide as Trump vows to cut US prescription drug prices ‘by 30-80%'
President plans to use executive powers, saying US should pay ‘same price as nation that pays the lowest price'
GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis
PHILADELPHIA--(BUSINESS WIRE)-- #Adolescents--GSK and Lifetime® launch original movie to raise awareness about the impact of meningitis.
EU drugs regulator confirms suicidal thoughts as side effect of anti hair-loss drug
The European drugs regulator said on Thursday its safety committee has confirmed suicidal thoughts as a side effect of Organon's anti hair-loss drug finasteride, following an EU-wide review of availab...
New vaccine chief rocks pharmaceutical stocks
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump.
5 Reasons GSK Looks Good
GSK's stock price has significantly outperformed the healthcare sector this year, supported by its healthy Q1 2025 numbers. Both turnover and EPS growth exceeded expectations, and the company's guidan...
GSK plc (GSK) Q1 2025 Earnings Conference Call Transcript
GSK plc (NYSE:GSK) Q1 2025 Earnings Conference Call April 30, 2025 7:00 AM ET Company Participants Constantin Fest - Head of IR Emma Walmsley - CEO Luke Miels - Chief Commercial Officer Julie Brown -...
Cervarix Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts | GSK Leads Cervarix Market Amid Global Vaccination Efforts
The Cervarix market report offers a comprehensive analysis of market size, growth potential, and segmentation, highlighting trends across major regions. Key drivers include rising HPV awareness, vacci...
Britain's GSK Asserts It Is 'Well Positioned' To Mitigate Potential Tariffs After Strong Q1 Cancer And HIV Drug Sales
On Wednesday, British multinational pharmaceutical GSK Plc GSK reported first-quarter sales of $9.46 billion (7.52 billion Sterling Pounds), up 2% year-over-year and 4% on constant currency. Analysts ...
GSK Posts Strong Results, Says 'Well Positioned' in Case of Pharma Tariffs
U.S.-listed shares of GSK (GSK) are gaining in premarket trading Wednesday after the British pharma giant posted better-than-expected first-quarter results and said it was "well positioned" should the...
GSK Sales, Profit Rise on Boost from Cancer Drugs
The British pharmaceutical giant said that its first-quarter sales rose to 7.52 billion pounds from 7.36 billion pounds the year prior.
British drugmaker GSK says 'well positioned' to absorb tariff hit
British drugmaker GSK said on Wednesday it was "well positioned" to respond to any potential financial impact from sector-specific tariffs if they were implemented and it had identified options within...
Pharma firms maastraz
Jimmy Muchechetere, senior equity analyst at Investec, weighs in on the prospect of pharmaceutical tariffs and recent U.S. investment commitments from the sector.
LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed
The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.
UK approves combination therapies of GSK's blood cancer drug Blenrep
GSK said on Thursday two combination therapies with its cancer drug, Blenrep, have received approval from British authorities for the treatment of a type of blood cancer in adults who had received at ...
Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease
--76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --Enrollment completed ahead of schedule-- SOUTH SAN FRANCISCO, Calif., Apri...
AREXVY recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices
PHILADELPHIA--(BUSINESS WIRE)-- #Arexvy--AREXVY recommended for adults aged 50-59 at increased risk for severe RSV disease by US Advisory Committee on Immunization Practices.
GSK's 5-in-1 Meningococcal Vaccine PENMENVY Receives Positive Recommendation from US Advisory Committee on Immunization Practices
PHILADELPHIA--(BUSINESS WIRE)-- #Adolescents--GSK's 5-in-1 meningococcal vaccine PENMENVY receives positive recommendation from US Advisory Committee on Immunization Practices.
GSK in breach for misleading prescribing information on Omjjara, industry body says
British pharmaceutical giant GSK has not met required ethical and regulatory standards in its marketing and prescription information for its Omjjara drug, an industry self-regulatory body said on Tues...
Trump Says Pharmaceutical Tariffs Coming in Near Future
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporter...